Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma

被引:41
作者
Berger, David A.
Megwalu, Ifeanyichukwu I. [1 ]
Vlahiotis, Anna
Radwan, Mohamed H.
Serrano, Maria F.
Humphrey, Peter A.
Piccirillo, Jay F.
Kibel, Adam S.
机构
[1] Washington Univ, Sch Med, Div Urol,Dept Otolaryngol Head & Neck Surg, Clin Outcomes Res Off,Dept Pathol, St Louis, MO 63105 USA
关键词
D O I
10.1016/j.urology.2008.02.061
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Although the classification of cancer has traditionally focused on the gross and microscopic characteristics of the tumor, the overall health of patients can affect their survival. because patients with renal cell carcinoma often have other medical conditions, we explored the effect of preexisting medical disease on survival after radical and partial nephrectomy. METHODS From January 1995 to August 2003, the comorbidity status of 697 patients with nonmetastatic renal cell carcinoma who had undergone radical or partial nephrectomy was prospectively coded using the Adult Comorbidity Evaluation-27. Histopathologic review of all slides was performed according to the 2004 World Health Organization scheme. Other variables analyzed included age, sex, ethnicity, pathologic stage, Fuhrman grade, and tumor size. The effect of these factors on Overall survival (OS) was analyzed using COX proportional hazards regression model. RESULTS The median follow-up was 32.2 months for survivors and 36.5 months for all patients. The OS rate at 1, 3, and 5 years was 92.0% (641 patients), 75.3% (525 patients), and 52.7% (367 patients), respectively. Univariate analyses demonstrated that age, comorbidity, tumor size, Fuhrman grade, and pathologic stage were significant predictors of OS. Multivariate analysis revealed that age (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.10 to 1.82, P = .0067), comorbidity (HR 1.37, 95% CI 1.16 to 1.63, P = .0002), pathologic stage (HR 1.97, 95% CI 1.60 to 2.41, P < .0001), and grade (HR 1.83, 95% CI 1.28 to 2.59, P = .0008) predicted for OS. CONCLUSIONS The results of this Study have demonstrated that comorbidity is an independent prognostic factor for OS in patients with renal cell carcinoma. Capturing the comorbidity information using validated instruments can improve the preoperative evaluation of patients by providing more accurate prognostic information.
引用
收藏
页码:359 / 363
页数:5
相关论文
共 23 条
[1]   Disparities in treatment and outcome for renal cell cancer among older black and white patients [J].
Berndt, Sonja I. ;
Carter, H. Ballentine ;
Schoenberg, Mark P. ;
Newschaffer, Craig J. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3589-3595
[2]   PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].
FEINSTEIN, AR .
JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+
[3]   Solid renal tumors: An analysis of pathological features related to tumor size [J].
Frank, I ;
Blute, ML ;
Cheville, JC ;
Lohse, CM ;
Weaver, AL ;
Zincke, H .
JOURNAL OF UROLOGY, 2003, 170 (06) :2217-2220
[4]   Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension [J].
Gettman, MT ;
Boelter, CW ;
Cheville, JC ;
Zincke, H ;
Bryant, SC ;
Blute, ML .
JOURNAL OF UROLOGY, 2003, 169 (04) :1282-1286
[5]   Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population [J].
Han, KR ;
Bleumer, I ;
Pantuck, AJ ;
Kim, HL ;
Dorey, FJ ;
Janzen, NK ;
Zisman, A ;
Dinney, CP ;
Wood, CG ;
Swanson, DA ;
Said, JW ;
Figlin, RA ;
Mulders, PFA ;
Belldegrun, AS .
JOURNAL OF UROLOGY, 2003, 170 (06) :2221-2224
[6]   Rising incidence of small renal masses: A need to reassess treatment effect [J].
Hollingsworth, John M. ;
Miller, David C. ;
Daignault, Stephanie ;
Hollenbeck, Brent K. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (18) :1331-1334
[7]   Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
[8]   Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma [J].
Kim, HL ;
Seligson, D ;
Liu, XL ;
Janzen, N ;
Bui, MHT ;
Yu, H ;
Shi, T ;
Belldegrun, AS ;
Horvath, S ;
Figlin, RA .
JOURNAL OF UROLOGY, 2005, 173 (05) :1496-1501
[9]   Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma [J].
Kramer, BA ;
Gao, X ;
Davis, M ;
Hall, M ;
Holzbeierlein, J ;
Tawfik, O .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 201 (04) :565-570
[10]   Incidental renal tumors: Casting doubt on the efficacy of early intervention [J].
Parsons, JK ;
Schoenberg, MS ;
Carter, HB .
UROLOGY, 2001, 57 (06) :1013-1015